Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06373263

Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1

Sharing research results with patients is required by ethical regulations. Yet, most researchers do not share results from their studies with patients. The investigators plan to conduct a series of randomized controlled trials among people with scleroderma, a rare autoimmune disease, in a large international cohort, to identify the most effective methods for communicating study results with patients.

The first trial in the series will compare a research dissemination tool (infographic) against a plain-language summary comparator. Participants will be randomly assigned to receive the dissemination tool or comparator. Study participants will rate communication tools for (1) information completeness; (2) understandability; and (3) ease of use of format. Our results can be used by researchers and patient organizations who disseminate research results so that they can tailor the way they disseminate results to patient needs.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Background: Research ethics guidance mandates that study results be shared with participants, and CIHR's Knowledge Translation Strategy emphasizes dissemination to others with relevant lived experiences. Yet, most researchers do not share results with patients, and do not know which dissemination tools (e.g., lay summaries, infographics, podcasts) or tool features best facilitate effective communication. Only 3 randomized controlled trials (RCTs) have compared tool effectiveness, and none assessed which approaches work best for which patients. Comparative effectiveness trials are needed to build an evidence base to help us understand what tools are most effective for communicating different types of research to different patients. The investigators will use the multinational Scleroderma Patient-centered Intervention Network (SPIN) Cohort to conduct a series of RCTs to compare tools among people with systemic sclerosis, or scleroderma. The first trial in the series will compare a research dissemination tool (infographic) against a plain-language summary comparator.

Objectives: An effective tool must communicate information patients want to know, understandably, in an easy-to-use format. The trial will compare the effectiveness of an infographic and lay summary, overall and for patients with different sociodemographic or educational characteristics.

Primary Objectives: The first trial will compare tools based on (1) information completeness; (2) understandability; and (3) ease of use, as prioritized by our Patient Advisory Team.

Secondary Objectives: The investigators will evaluate comprehension of key aspects of disseminated research; likelihood that participants would enroll in a similar future study; and, for all primary and secondary outcomes, analyze effects by participant characteristics (e.g., age, country, language, education level, eHealth literacy).

Methods: Parallel-group RCT that will compare 2 tools (infographic and plain-language summary comparator. For this trial, SPIN patients and researchers will select systemic sclerosis research to disseminate. Tools will be developed by experienced tool developers, patients, and researchers. SPIN Cohort participants (N = 1,250 and growing) will be invited to enrol, and those enrolled will be randomized to a dissemination tool and complete outcomes. Response options will be 0 to 10 numerical rating scales (0 = strongly disagree, 10 = strongly agree). The primary analysis will be intention-to-treat, using a linear mixed effects model with multiple observations per participant (using the lmer function from the lme4 package in R).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Enrollment in SPIN Cohort, which requires a systemic sclerosis (SSc) classification by a site physician based on 2013 American College of Rheumatology/European League Against Rheumatism criteria, ≥18 years old, being fluent in English or French, and have completed one SPIN Cohort assessment in the last year.
  • External enrollment with patient-reported physician classification of SSc and age 18 or older.

Exclusion criteria

Patients not able to access or respond to questionnaires via the internet are excluded.

Treatment and study plan

Plain-language summary

Other

Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be < 500 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.

Dissemination Tool (Infographic)

Other

The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.

Primary outcomes

  1. Completeness

    Time frame: Immediately Post-intervention (intervention and outcomes in one login - outcomes approx 30 min after randomization)

    "The information presented in the [tool - e.g., "infographic", "plain-language summary"] told me everything I wanted to know about the study".

    Response options = 0-10 numerical rating scales (0 = strongly disagree, 10 = strongly agree)

  2. Understandability

    Time frame: Immediately Post-intervention (intervention and outcomes in one login - outcomes approx 30 min after randomization)

    "The information presented in the [tool] was easy to understand". Response options = 0-10 numerical rating scales (0 = strongly disagree, 10 = strongly agree)

  3. Ease of use

    Time frame: Immediately Post-intervention (intervention and outcomes in one login - outcomes approx 30 min after randomization)

    "The [tool] was designed in a way that made it easy to use". Response options = 0-10 numerical rating scales (0 = strongly disagree, 10 = strongly agree)

Secondary outcomes

  1. Please to have received results

    Time frame: Immediately Post-intervention (intervention and outcomes in one login - outcomes approx 30 min after randomization)

    "I am glad that I received the study results"); Response options = 0-10 numerical rating scales (0 = strongly disagree, 10 = strongly agree)

  2. Intention to participate in future studies

    Time frame: Immediately Post-intervention (intervention and outcomes in one login - outcomes approx 30 min after randomization)

    "In the future, I would agree to participate in a similar study to the one presented in the [tool]". Response options = 0-10 numerical rating scales (0 = strongly disagree, 10 = strongly agree)

  3. Open-ended items

    Time frame: Immediately Post-intervention (intervention and outcomes in one login - outcomes approx 30 min after randomization)

    "What did you like about the way the information was communicated?"; "What did you dislike about the way the information was communicated?"; "Do you have suggestions for improving how the information is communicated?"

Study contacts

Contact information is provided by the study sponsor or research team.

Brett D Thombs, PhD

CONTACT

[email protected]

514-340-8222 ext. 24244

Marie-Eve Carrier, MSc

CONTACT

[email protected]

514-265-8676

Sponsors and collaborators

Lead sponsor

Lady Davis Institute

Other

Registry information

Official study title

A Randomized Controlled Trial to Compare the Effectiveness of Dissemination Tools to Share Research Results With Patients - SPIN-CLEAR Trial #1

Acronym: SPIN-CLEAR #1

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Apr 18, 2024
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.